*For reference by medical professionals only Antibody-drug conjugates (ADCs) have become a new hotspot in the field of anti-tumor therapy, with explorations in the treatment of breast cancer, lung cancer, gastric cancer, colorectal cancer, and other types of cancer. With the approval and clinical entry of drugs such as Trastuzumab Deruxtecan, Ado-trastuzumab emtansine, and Enfortumab … Read more
Since 2000, the ADC field has gradually started to be pushed to market, and in recent years, it has emerged rapidly in the field of cancer treatment, leading to intense competition. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology areas. Although the number of related ADCs is extremely limited and most … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxic side effects of traditional small molecule drugs and enhancing overall therapeutic efficiency. Currently, there are 13 ADC … Read more
The purpose of this article is to introduce the theory and knowledge related to high-speed ADCs, detailing sampling theory, data sheet specifications, ADC selection criteria and evaluation methods, clock jitter, and other general system-level considerations. Additionally, some users hope to further enhance the performance of ADCs through techniques such as interleaving, averaging, or dithering. 1. … Read more
ADC drug conjugation refers to the method of linking various components of ADC, which determines the drug-antibody conjugation ratio (DAR) and homogeneity, affecting the drug’s activity, tolerance, and stability. It is generally divided into random coupling and site-specific coupling. Non-Site-Specific Coupling Common methods include coupling at Lys residues and Cys residues. Site-Specific Coupling, which includes … Read more
Antibody-drug conjugates (ADCs) consist of linkers, payloads, and monoclonal antibodies (mAbs). They combine the advantages of high specificity targeting and potent cytotoxic effects, achieving precise and efficient elimination of cancer cells, making them a hot topic in cancer drug development. Since the first ADC drug Mylotarg® was approved by the FDA in 2000, as of … Read more
Introduction Antibody-drug conjugates (ADCs) consist of antibodies, linkers, and cytotoxic payloads. Compared to traditional chemotherapy, ADCs target tumors with the promise of reducing systemic toxicity, providing a broader therapeutic window and a higher therapeutic index. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary … Read more
In today’s circuit design, the vast majority of scenarios involve mixed-signal circuit designs that integrate both digital and analog components, and the intermediate connection channels in mixed circuits inevitably rely on ADC and DAC. For example, the joystick inside our daily remote controls operates on the principle of a sliding potentiometer. Some higher-end designs use … Read more
Author | Little Fish Periodically, major pharmaceutical media and authoritative journals summarize the development of ADCs. Recently, a review on ADCs published by the internationally renowned journal ACS caught our attention. As a member of CAS (American Chemical Society), Janet M. Sasso’s team innovatively used patents and articles related to ADCs within CAS as data … Read more
Representative ADC Technology Platforms As a combination drug, any component of an ADC can be replaced or modified.Therefore, the ADC combination technology platform has significant extensibility, allowing for the iterative combination of a rich variety of products.The development history of internationally leading ADC companies is rooted in having a competitive platform.Table 1 lists several representative … Read more